BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33628205)

  • 1. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.
    Foxall R; Narang P; Glaysher B; Hub E; Teal E; Coles MC; Ashton-Key M; Beers SA; Cragg MS
    Front Immunol; 2020; 11():605231. PubMed ID: 33628205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.
    Sabhachandani P; Sarkar S; Mckenney S; Ravi D; Evens AM; Konry T
    J Control Release; 2019 Feb; 295():21-30. PubMed ID: 30550941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.
    Ling HY; Yang Z; Wang PJ; Sun Y; Ju SG; Li J; Fu JX
    Chem Biol Interact; 2022 Jan; 352():109779. PubMed ID: 34922904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment.
    Rebelo SP; Pinto C; Martins TR; Harrer N; Estrada MF; Loza-Alvarez P; Cabeçadas J; Alves PM; Gualda EJ; Sommergruber W; Brito C
    Biomaterials; 2018 May; 163():185-197. PubMed ID: 29477032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
    Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
    Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 3D NSCLC Cell Cultures with Fibroblasts or Macrophages for Tumor Microenvironment Studies and Chemotherapy Screening.
    Garnique ADMB; Machado-Santelli GM
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.
    Matsuki E; Bohn OL; El Jamal S; Pichardo JD; Zelenetz AD; Younes A; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):572-580. PubMed ID: 30106758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.
    Ren S; Cai Y; Hu S; Liu J; Zhao Y; Ding M; Chen X; Zhan L; Zhou X; Wang X
    Biochem Pharmacol; 2021 Jun; 188():114576. PubMed ID: 33930347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a Desmoplastic Tumor Microenvironment for Colon Cancer Drug Sensitivity: A Study with 3D Chimeric Tumor Spheroids.
    Goudar VS; Koduri MP; Ta YN; Chen Y; Chu LA; Lu LS; Tseng FG
    ACS Appl Mater Interfaces; 2021 Oct; 13(41):48478-48491. PubMed ID: 34633791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform.
    Goodwin ML; Urs SK; Simeone DM
    Methods Mol Biol; 2019; 1882():73-80. PubMed ID: 30378045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.
    Dumontet E; Mancini SJC; Tarte K
    Front Immunol; 2021; 12():784691. PubMed ID: 34956214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Co-Culture System of Three-Dimensional Tumor-Associated Macrophages and Three-Dimensional Cancer-Associated Fibroblasts Combined with Biomolecule Release for Cancer Cell Migration.
    Nii T; Kuwahara T; Makino K; Tabata Y
    Tissue Eng Part A; 2020 Dec; 26(23-24):1272-1282. PubMed ID: 32434426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
    Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
    Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
    Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
    Front Immunol; 2021; 12():656364. PubMed ID: 34122412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model.
    Cremasco F; Menietti E; Speziale D; Sam J; Sammicheli S; Richard M; Varol A; Klein C; Umana P; Bacac M; Colombetti S; Perro M
    PLoS One; 2021; 16(1):e0241091. PubMed ID: 33406104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.